Metabolites of purine nucleoside Phosphorylase (NP) in serum have the potential to delineate Pancreatic Adenocarcinoma

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Vareed, Shaiju K ^a,d   Bhat, Vadiraja B ^b,f   Thompson, Christopher ^b   Vasu, Vihas T ^a   Fermin, Damian ^c   Choi, Hyungwon ^b   Creighton, Chad J ^d   Gayatri, Sitaram ^a,e   Lan, Ling ^a   Putluri, Nagireddy ^a,d   Thangjam, Gagan Singh ^a   Kaur, Punit ^b   Shabahang, Mohsen ^b   Giri, Judith G ^a   Nesvizhskii, Alexey I ^c   Asea, Alexander A A ^b   Cashikar, Anil G ^a   Rao, Arundhati ^b   McLoughlin, James ^a   Sreekumar, Arun ^a,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^f AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALPHA SYNUCLEIN; DJ 1 PROTEIN; GUANOSINE; PURINE NUCLEOSIDE PHOSPHORYLASE; BIOLOGICAL MARKER; PROTEOME; TUMOR PROTEIN;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; NON INVASIVE MEASUREMENT; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS TUMOR; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; BLOOD; ENZYMOLOGY; METABOLISM; PROTEOMICS; REPRODUCIBILITY;

BIOLOGICAL MARKERS; HUMANS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEOME; PROTEOMICS; PURINE-NUCLEOSIDE PHOSPHORYLASE; REPRODUCIBILITY OF RESULTS;

EID: 79952940973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017177     Document Type: Article

References (81)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Warshaw AL, Fernandez-del Castillo C, (1992) Pancreatic carcinoma. N Engl J Med 326: 455-465.
3. Goggins M, Canto M, Hruban R, (2000) Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 74: 243-248.
4. Rosty C, Goggins M, (2002) Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 16: 37-52.
5. Farrell JJ, van Rijnsoever M, Elsaleh H, (2005) Early detection markers in Pancreas Cancer. Cancer Biomark 1: 157-175.
6. Ritts RE, Pitt HA, (1998) CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 7: 93-101.
7. Boeck S, Haas M, Laubender RP, Kullmann F, Klose C, et al. (2010) Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 16: 986-994.
8. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP, (2004) Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11: 644-649.
9. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V, (2006) Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70: 255-264.
10. Li YG, Zhang N, (2009) Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis 41: 605-608.
11. Park IJ, Choi GS, Jun SH, (2009) Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res 29: 4303-4308.
12. Chintanaboina J, Badari AR, Gopavaram D, Qazi KJ, (2008) Transient marked elevation of serum CA 19-9 levels in a patient with acute cholangitis and biliary stent. South Med J 101: 661.
13. Yoshioka M, Shibata S, Sato T, Furuya T, Asanuma Y, et al. (2002) Management of pancreatic mass accompanying chronic pancreatitis. J Hepatobiliary Pancreat Surg 9: 376-378.
14. Cui Y, Zhang D, Jia Q, Li T, Zhang W, et al. (2009) Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma. Cancer Invest 27: 747-755.
15. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, et al. (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 852: 257-267.
16. Chen R, Pan S, Cooke K, Moyes KW, Bronner MP, et al. (2007) Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34: 70-79.
17. Zhao J, Qiu W, Simeone DM, Lubman DM, (2007) N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res 6: 1126-1138.
18. Chen R, Pan S, Yi EC, Donohoe S, Bronner MP, et al. (2006) Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6: 3871-3879.
19. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, et al. (2006) Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171.
20. Ringel J, Jesnowski R, Moniaux N, Luttges J, Choudhury A, et al. (2006) Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 66: 9045-9053.
21. Chen R, Pan S, Brentnall TA, Aebersold R, (2005) Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 4: 523-533.
22. Gronborg M, Bunkenborg J, Kristiansen TZ, Jensen ON, Yeo CJ, et al. (2004) Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3: 1042-1055.
23. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer 9: 149.
24. Tonack S, Aspinall-O'Dea M, Neoptolemos JP, Costello E, (2009) Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology 9: 567-576.
25. Chung JC, Oh MJ, Choi SH, Bae CD, (2008) Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J Surg 78: 245-251.
26. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, et al. (2005) Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129: 1454-1463.
27. Cui Y, Tian M, Zong M, Teng M, Chen Y, et al. (2009) Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology 9: 89-98.
28. Schneider MU, Rosch W, Domschke S, Domschke W, (1984) Pancreatic juice protein associated with chronic pancreatitis and adenocarcinoma of the pancreas. Scand J Gastroenterol 19: 139-144.
29. Ortsater H, Sundsten T, Lin JM, Bergsten P, (2007) Evaluation of the SELDI-TOF MS technique for protein profiling of pancreatic islets exposed to glucose and oleate. Proteomics 7: 3105-3115.
30. Zhou L, Lu Z, Yang A, Deng R, Mai C, et al. (2007) Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 7: 1345-1355.
31. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, et al. (2008) Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8: 241.
32. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, et al. (2007) Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 1774: 764-771.
33. Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, et al. (2009) Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res 8: 1647-1656.
34. van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, et al. (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69: 629-634.
35. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259.
36. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, et al. (2003) DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24: 159-160.
37. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
38. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
39. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, et al. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274: 1197-1199.
40. Storey J, (2002) A direct approach to false discovery rates. Journal of the Royal Statistical Society 64: 479-498.
41. Roberts EL, Newton RP, Axford AT, (2004) Plasma purine nucleoside phosphorylase in cancer patients. Clin Chim Acta 344: 109-114.
42. Hidalgo M, Pancreatic cancer. N Engl J Med 362: 1605-1617.
43. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, et al. (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26: 41-50.
44. Chesselet MF, (2008) In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol 209: 22-27.
45. Mougenot AL, Betemps D, Hogeveen KN, Kovacs GG, Chouaf-Lakhdar L, et al. Production of a monoclonal antibody, against human alpha-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the alpha-synuclein locus. J Neurosci Methods.
46. Matsuo Y, Kamitani T, Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One 5: e10481.
47. Ye Q, Wang TF, Peng YF, Xie J, Feng B, et al. Expression of alpha-, beta- and gamma-synuclein in colorectal cancer, and potential clinical significance in progression of the disease. Oncol Rep 23: 429-436.
48. Ye Q, Feng B, Peng YF, Chen XH, Cai Q, et al. (2009) Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116. World J Gastroenterol 15: 5035-5043.
49. Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, et al. (2009) Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res 15: 2864-2871.
50. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM, (2007) Gamma-synuclein and the progression of cancer. FASEB J 21: 3419-3430.
51. Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, et al. (2004) Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer 101: 58-65.
52. Gupta A, Inaba S, Wong OK, Fang G, Liu J, (2003) Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene 22: 7593-7599.
53. Jia T, Liu YE, Liu J, Shi YE, (1999) Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res 59: 742-747.
54. Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ, et al. (2009) Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 114: 293-298.
55. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
56. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, et al. (2007) Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem 53: 629-635.
57. Xu X, Martin F, Friedman JS, The familial Parkinson's disease gene DJ-1 (PARK7) is expressed in red cells and plays a role in protection against oxidative damage. Blood Cells Mol Dis 45: 227-232.
58. Xu J, Zhong N, Wang H, Elias JE, Kim CY, et al. (2005) The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14: 1231-1241.
59. Kim YC, Kitaura H, Iguchi-Ariga SM, Ariga H, DJ-1, an oncogene and causative gene for familial Parkinson's disease, is essential for SV40 transformation in mouse fibroblasts through up-regulation of c-Myc. FEBS Lett 584: 3891-3895.
60. Mo JS, Jung J, Yoon JH, Hong JA, Kim MY, et al. DJ-1 modulates the p38 mitogen-activated protein kinase pathway through physical interaction with apoptosis signal-regulating kinase 1. J Cell Biochem 110: 229-237.
61. Morris PE Jr, Omura GA, (2000) Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis. Curr Pharm Des 6: 943-959.
62. Conry RM, Bantia S, Turner HS, Barlow DL, Allen KO, et al. (1998) Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. Immunopharmacology 40: 1-9.
63. Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, et al. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes-a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol 10: 784-790.
64. Mesarosova A, Hrivnakova A, Babusikova O, (1993) Acute myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype. Neoplasma 40: 341-345.
65. Dalal I, Grunebaum E, Cohen A, Roifman CM, (2001) Two novel mutations in a purine nucleoside phosphorylase (PNP)-deficient patient. Clin Genet 59: 430-437.
66. Markert ML, Finkel BD, McLaughlin TM, Watson TJ, Collard HR, et al. (1997) Mutations in purine nucleoside phosphorylase deficiency. Hum Mutat 9: 118-121.
67. Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK, (1975) Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1: 1010-1013.
68. Rebours V, Levy P, Mosnier JF, Scoazec JY, Soubeyrand MS, et al. Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. Clin Gastroenterol Hepatol 8: 206-212.
69. Kang TH, Bae KH, Yu MJ, Kim WK, Hwang HR, et al. (2007) Phosphoproteomic analysis of neuronal cell death by glutamate-induced oxidative stress. Proteomics 7: 2624-2635.
70. Bhat VB, Choi MH, Wishnok JS, Tannenbaum SR, (2005) Comparative plasma proteome analysis of lymphoma-bearing SJL mice. J Proteome Res 4: 1814-1825.
71. Kristiansson MH, Bhat VB, Babu IR, Wishnok JS, Tannenbaum SR, (2007) Comparative time-dependent analysis of potential inflammation biomarkers in lymphoma-bearing SJL mice. J Proteome Res 6: 1735-1744.
72. Schirle M, Heurtier MA, Kuster B, (2003) Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2: 1297-1305.
73. Breci L, Hattrup E, Keeler M, Letarte J, Johnson R, et al. (2005) Comprehensive proteomics in yeast using chromatographic fractionation, gas phase fractionation, protein gel electrophoresis, and isoelectric focusing. Proteomics 5: 2018-2028.
74. Shevchenko A, Wilm M, Vorm O, Mann M, (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
75. Nikov G, Bhat V, Wishnok JS, Tannenbaum SR, (2003) Analysis of nitrated proteins by nitrotyrosine-specific affinity probes and mass spectrometry. Anal Biochem 320: 214-222.
76. Horth P, Miller CA, Preckel T, Wenz C, (2006) Efficient fractionation and improved protein identification by peptide OFFGEL electrophoresis. Mol Cell Proteomics 5: 1968-1974.
77. Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R, et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 9: 298-312.
78. Nesvizhskii AI, Aebersold R, (2005) Interpretation of shotgun proteomic data: the protein inference problem. Mol Cell Proteomics 4: 1419-1440.
79. R Development Core Team (2008) R: A language and environment for statistical computing. R Foundation for Statistical Computing.
80. Saldanha AJ, (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248.
81. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.